Release of lactoferrin and elastase in human allergic skin reactions.
Our previous skin chamber studies have shown prominent accumulation of viable neutrophils in human allergic skin reaction sites. To determine whether such neutrophils release components that may be pathogenic in allergic reactions, we have compared the patterns of release of five components: 1) lactoferrin, present in specific granules; 2) and 3) elastase and myeloperoxidase, present mainly in azurophilic granules; 4) lactic dehydrogenase, a cytosolic component generally released during cell damage; 5) histamine, present in mast cells and basophils but not in neutrophils. In 13 pollen-sensitive subjects we found that continuous antigen challenge for 5 h lead to a peak of histamine release into overlying skin chambers during the 1st h, followed by a plateau of low level histamine release over the succeeding 4 h. In contrast, there was no significantly increased released of lactoferrin or elastase during the first h, but significantly increased accumulation of these components at Ag challenge sites over the next 4 h. There was no significant difference at Ag vs buffer control sites in the levels of either myeloperoxidase or lactic dehydrogenase. The increased levels of lactoferrin and elastase at antigen challenge sites in the 2nd to 5th h were not simply a reflection of the greater numbers of neutrophils present in such sites because the levels of these components did not correlate significantly with the number of neutrophils in chamber fluids obtained from individual sites. However, such lactoferrin levels did correlate significantly with the amount of histamine released earlier during the 1st h of Ag challenge at individual sites. These findings suggest a selective in vivo release of neutrophil components in IgE-mediated human allergic skin reactions, possibly related in degree to earlier mast cell activation. Inasmuch as lactoferrin likely plays a role in reactive oxidants effects and elastase is a potent nonspecific protease, release of these agents could play a pathogenic role in late phase allergic reactions.
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104.
B
B
Zweiman
U
U
Kucich
M
M
Shalit
C
C
Von Allmen
A
A
Moskovitz
G
G
Weinbaum
P C
PC
Atkins
D000328:Adult; D006632:Histamine / Q000378:metabolism; D006636:Histamine Release; D006801:Humans; D006967:Hypersensitivity / Q000201:enzymology*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D007781:Lactoferrin / Q000378:metabolism*; D007782:Lactoglobulins / Q000378:metabolism*; D009504:Neutrophils / Q000378:metabolism; D010196:Pancreatic Elastase / Q000378:metabolism*; D009195:Peroxidase / Q000378:metabolism; D012867:Skin / Q000201:enzymology / Q000276:immunology*
D007782:Lactoglobulins; D006632:Histamine; D007770:L-Lactate Dehydrogenase; D009195:Peroxidase; D007781:Lactoferrin; D010196:Pancreatic Elastase